Newly launched algorithm reduces image artifacts in real-time during IR procedures
GE HealthCare’s new artificial intelligence algorithm promises to offer improvements in the quality of cone-beam computed tomography (CBCT) images captured during interventional procedures.
The healthcare giant announced the launch of CleaRecon DL earlier this week. The deep learning algorithm is said to reduce the appearance of artifacts caused by blood flow pulsations that occur in the arteries during multiple IR procedures. These artifacts can diminish image quality and, consequently, procedural accuracy.
Clinical validation testing proved CleaRecon DL’s 3D image reconstructions to be effective at reducing unwanted artifacts, offering clearer images in 98% of the cases included in the assessment. What’s more, the improved visibility also enhanced providers’ confidence in their image interpretations in 94% of cases.
Arnaud Marie, general manager of Interventional Solutions at GE HealthCare, believes the launch of the new algorithm is well timed with the growing use of CBCT.
“By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence,” Marie said in a news release on the announcement. “This solution builds on our portfolio of tools aimed at improving the user experience and workflow efficiency, enabling clinicians to deliver more accurate and effective interventions for enhanced patient outcomes.”
"CleaRecon DL takes CBCT to the next level, enabling clinicians to confidently use CBCT on patients with tools that help us provide the highest quality imaging and treatment across a wide range of clinical scenarios,” added Charles Nutting, MD, an interventional radiologist at Image Guided Therapy in Denver, Colorado. “This advancement improves our ability to perform precise interventions, with less manipulation of the image and eliminates artifacts that have historically hindered image clarity, ultimately helping improve the care clinicians can provide to patients.”
The algorithm, which was recently approved by the U.S. Food and Drug Administration, is available in the U.S. and Europe on GE’s Allia IR platform.
Learn more about CleaRecon DL here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.